A large-scale analysis of 68,960 US dementia patients found that those receiving the recombinant zoster vaccine Shingrix within two years of diagnosis experienced a 26% reduction in all-cause mortality during the first year of follow-up, with sustained benefits over three years. The vaccine group also showed significantly slower cognitive decline on Mini-Mental State Examinations compared to controls who received other vaccines. This represents a potentially groundbreaking finding for dementia care, where effective disease-modifying treatments remain scarce. The mechanism likely involves the vaccine's broader immunomodulatory effects beyond herpes zoster prevention, possibly reducing neuroinflammation that accelerates cognitive deterioration. The study's strength lies in its massive cohort size and propensity-score matching methodology, though as an observational design it cannot establish causation. The finding builds on previous research linking Shingrix to reduced dementia incidence, now extending benefits to those already diagnosed. However, this preprint awaits peer review, and results may change upon scrutiny. If validated, this could represent a paradigm-shifting intervention—transforming a routine vaccine into a potential dementia treatment with profound implications for millions of patients worldwide.